
COMPASS Pathways (CMPS) Stock Forecast & Price Target
COMPASS Pathways (CMPS) Analyst Ratings
Bulls say
Compass Pathways PLC is well-positioned for growth due to the anticipated Phase III clinical trial data expected in the latter half of the quarter, with potential share value doubling on positive outcomes and heightened visibility towards regulatory approval. The company has increased its probability of success to 75%, supported by strong Phase IIb results showing notable improvements in measured depression scales and a solid infrastructure for trial conduct and commercial rollout. Additionally, the expansion of treatment options and the strengthening intellectual property surrounding COMP360, combined with a favorable regulatory environment and growing patient enthusiasm, contribute to a robust outlook for Compass Pathways in the mental health therapeutic market.
Bears say
Compass Pathways PLC faces substantial risks that could adversely impact its stock performance, primarily tied to the clinical success of its proprietary psilocybin formulation, COMP360, particularly in upcoming Phase III trials. Should COMP360 fail to demonstrate clinically meaningful benefits, encounter safety concerns, or struggle with commercialization and regulatory approval, it could prompt significant downward adjustments in the company's valuation and stock price. Additionally, broader caution in the psychedelic sector, competitive pressures, and financial constraints related to ongoing R&D and SG&A expenditures further exacerbate the negative outlook for the company's financial trajectory.
This aggregate rating is based on analysts' research of COMPASS Pathways and is not a guaranteed prediction by Public.com or investment advice.
COMPASS Pathways (CMPS) Analyst Forecast & Price Prediction
Start investing in COMPASS Pathways (CMPS)
Order type
Buy in
Order amount
Est. shares
0 shares